
Yves Chalandon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2079822/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica, 2022, 107, 1054-1063.	1.7	20
2	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 23-30.	1.3	4
3	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. Pharmacogenomics Journal, 2022, 22, 9-18.	0.9	1
4	Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?. Open Forum Infectious Diseases, 2022, 9, ofab596.	0.4	12
5	Rhinovirus Infections among Hematopoietic Stem Cell Transplant Recipients: A Pre-Transplant Dilemma?. Viruses, 2022, 14, 267.	1.5	7
6	Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors – first 10 years of prospective donor follow-up of Swiss donors. Bone Marrow Transplantation, 2022, 57, 918-924.	1.3	4
7	Frequency and causes of antifungal treatment changes in allogeneic haematopoÃ ⁻ etic cell transplant recipients with invasive mould infections. Mycoses, 2022, 65, 199-210.	1.8	2
8	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 1072-1078.	1.3	4
9	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2022, 57, 1421-1427.	1.3	7
10	Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts. Transplantation and Cellular Therapy, 2021, 27, 67.e1-67.e7.	0.6	1
11	Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. Annals of Hematology, 2021, 100, 209-216.	0.8	13
12	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 2021, 13, 672.	1.7	7
13	Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1593-1602.	1.3	8
14	Risk factors for a severe form of COVIDâ€19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGMâ€TC) multicentre cohort study. British Journal of Haematology, 2021, 192, e121-e124.	1.2	36
15	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation, 2021, 56, 1944-1952.	1.3	7
16	Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. Vaccines, 2021, 9, 372.	2.1	22
17	Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	5
18	Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in highâ€risk hematopoietic cell transplant recipients. Immunity, Inflammation and Disease, 2021, 9, 771-776.	1.3	13

#	Article	IF	CITATIONS
19	The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft. Bone Marrow Transplantation, 2021, 56, 2284-2286.	1.3	0
20	Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience. Mycopathologia, 2021, 186, 775-788.	1.3	5
21	Successful treatment of central nervous system lymphoproliferative disorder in a kidney-pancreas and stem cell transplanted patient using intrathecal rituximab. BMJ Case Reports, 2021, 14, e238236.	0.2	3
22	Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2021, 56, 3094-3096.	1.3	28
23	Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation. Blood Advances, 2021, 5, 3377-3386.	2.5	7
24	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	4
25	Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation. Journal of Fungi (Basel, Switzerland), 2021, 7, 811.	1.5	2
26	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Medical Mycology, 2021, 59, 701-711.	0.3	8
27	Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2. Blood, 2021, 138, 1232-1232.	0.6	10
28	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWPâ€EBMT study. British Journal of Haematology, 2020, 188, 745-756.	1.2	20
29	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Biology of Blood and Marrow Transplantation, 2020, 26, 936-942.	2.0	15
30	Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children. Therapeutic Drug Monitoring, 2020, 42, 111-117.	1.0	13
31	Conditioningâ€based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991â€2012) on behalf of EBMT CMWP. European Journal of Haematology, 2020, 104, 181-189.	1.1	7
32	Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation. Leukemia, 2020, 34, 1422-1432.	3.3	20
33	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 920-927.	2.0	11
34	Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, ofaa246.	0.4	7
35	Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Advances, 2020, 4, 3699-3707.	2.5	17
36	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood Advances, 2020, 4, 4267-4277.	2.5	14

#	Article	IF	CITATIONS
37	Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm. Leukemia and Lymphoma, 2020, 61, 2226-2229.	0.6	1
38	Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 998.	2.2	25
39	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. Journal of Clinical Oncology, 2020, 38, 1518-1526.	0.8	34
40	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia, 2020, 34, 1730-1740.	3.3	21
41	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 2020, 34, 1751-1759.	3.3	18
42	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5â€year analysis within the Swiss Transplant Cohort study. Transplant Infectious Disease, 2020, 22, e13289.	0.7	11
43	Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study. Blood, 2020, 136, 328-338.	0.6	23
44	Intracellular Pathogen in the Cerebrospinal Fluid of an Allogeneic Hematopoietic Cell Transplant Recipient With Graft-Versus-Host Disease and Brain Lesions. Clinical Infectious Diseases, 2020, 71, 3005-3008.	2.9	0
45	Human pegivirus persistence in human blood virome after allogeneic haematopoietic stem-cell transplantation. Clinical Microbiology and Infection, 2019, 25, 225-232.	2.8	28
46	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2366-2374.	2.0	3
47	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. Biology of Blood and Marrow Transplantation, 2019, 25, 2008-2016.	2.0	20
48	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2167-2171.	2.0	69
49	Epigenetic Silencing Affects <scp>l</scp> -Asparaginase Sensitivity and Predicts Outcome in T-ALL. Clinical Cancer Research, 2019, 25, 2483-2493.	3.2	25
50	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. Haematologica, 2019, 104, 1230-1236.	1.7	12
51	Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2019, 10, 1034.	2.2	39
52	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica, 2019, 104, 659-668.	1.7	56
53	High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1701-1709.	1.3	15
54	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica, 2019, 104, 1782-1788.	1.7	48

4

#	Article	IF	CITATIONS
55	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1981-1988.	2.5	12
56	DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY. Hematological Oncology, 2019, 37, 316-317.	0.8	0
57	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 522-528.	2.0	48
58	Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 1022-1028.	1.3	19
59	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood, 2019, 133, 280-284.	0.6	48
60	Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. Blood, 2019, 134, 3335-3335.	0.6	1
61	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. Blood, 2019, 134, 1295-1295.	0.6	4
62	Myeloproliferative Neoplasms. , 2019, , 569-578.		1
63	Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. Bone Marrow Transplantation, 2018, 53, 1072-1075.	1.3	0
64	Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α. Oncologist, 2018, 23, 719-721.	1.9	13
65	Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2018, 59, 590-600.	0.6	3
66	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiology, 2018, 52, 55-62.	0.8	8
67	Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance. Therapeutic Drug Monitoring, 2018, 40, 84-92.	1.0	22
68	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. Journal of Clinical Oncology, 2018, 36, 2514-2523.	0.8	99
69	Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. Transplant Infectious Disease, 2018, 20, e12981.	0.7	35
70	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of <scp>EBMT</scp> . British Journal of Haematology, 2018, 182, 418-422.	1.2	28
71	Central nervous system graft-versus-host disease (CNS-GvHD) after allogeneic haematopoietic stem cell transplantation. BMJ Case Reports, 2018, 2018, bcr-2017-221840.	0.2	13
72	Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997–2016. Swiss Medical Weekly, 2018, 148, w14589.	0.8	2

#	Article	IF	CITATIONS
73	Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation. Leukemia and Lymphoma, 2017, 58, 470-472.	0.6	2
74	FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission. Hematological Oncology, 2017, 35, 392-394.	0.8	0
75	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood, 2017, 129, 1636-1645.	0.6	77
76	Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient. International Journal of Infectious Diseases, 2017, 55, 24-26.	1.5	12
77	Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2017, 177, 759-765.	1.2	38
78	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood, 2017, 130, 1832-1844.	0.6	66
79	The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Pharmacology, 2017, 8, 451.	1.6	8
80	TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. Frontiers in Medicine, 2017, 4, 149.	1.2	30
81	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget, 2017, 8, 90852-90867.	0.8	39
82	Improvement of Relative Survival in Elderly Patients with Acute Myeloid Leukemia Emerging from Population-Based Cancer Registries in Switzerland from 2001-2013. Blood, 2017, 130, 863-863.	0.6	0
83	A Protective Role of DNA Repair Genes Against Acute Graft Versus Host Disease in Children. Blood, 2017, 130, 749-749.	0.6	0
84	Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 362.	2.2	55
85	Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2016, 22, 1615-1620.	2.0	46
86	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016, 375, 1044-1053.	13.9	270
87	Torque teno virus in patients undergoing allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplantation, 2016, 51, 440-442.	1.3	37
88	Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants. Bone Marrow Transplantation, 2016, 51, 860-862.	1.3	4
89	Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. Bone Marrow Transplantation, 2016, 51, 955-960.	1.3	6
90	Efficient Prophylaxis with Defibrotide for Sinusoidal Obstruction Syndrome (SOS) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2016, 128, 2204-2204.	0.6	6

Yves Chalandon

#	Article	IF	CITATIONS
91	Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study. Blood, 2016, 128, 2777-2777.	0.6	2
92	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. Blood, 2016, 128, 3499-3499.	0.6	2
93	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Blood, 2016, 128, 4617-4617.	0.6	1
94	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. Blood, 2016, 128, 628-628.	0.6	1
95	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. Blood, 2016, 128, 762-762.	0.6	13
96	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation Blood, 2016, 128, 522-522.	0.6	0
97	Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party. Blood, 2016, 128, 4655-4655.	0.6	1
98	Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT. Blood, 2016, 128, 4685-4685.	0.6	2
99	Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood, 2015, 125, 2486-2496.	0.6	233
100	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 2015, 171, 239-246.	1.2	80
101	NK Cell Functional Impairment after Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Reduced Levels of T-bet and Eomesodermin. Journal of Immunology, 2015, 195, 4712-4720.	0.4	31
102	Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies. Bone Marrow Research, 2015, 2015, 1-6.	1.7	9
103	Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. Bone Marrow Research, 2015, 2015, 1-7.	1.7	8
104	Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 2015, 50, 790-794.	1.3	15
105	E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. Journal of Infectious Diseases, 2015, 212, 1726-1734.	1.9	54
106	Complete and sustained remission of spondyloarthritis after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. Joint Bone Spine, 2015, 82, 216-217.	0.8	7
107	High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities. Bone Marrow Transplantation, 2015, 50, 1201-1205.	1.3	15
108	Suggestive evidence of a role of HLA-DRB4 mismatches in the outcome of allogeneic hematopoietic stem cell transplantation with HLA-10/10-matched unrelated donors: a French–Swiss retrospective study. Bone Marrow Transplantation, 2015, 50, 1316-1320.	1.3	18

#	Article	IF	CITATIONS
109	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood, 2015, 125, 3711-3719.	0.6	291
110	Post-artesunate delayed haemolysis ‒ report of four cases and review of the literature. Swiss Medical Weekly, 2015, 145, w14181.	0.8	11
111	Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica, 2014, 99, 1492-1498.	1.7	19
112	The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplantation, 2014, 49, 55-61.	1.3	36
113	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood, 2014, 123, 3739-3749.	0.6	281
114	Validation of the Disease Risk Index for Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after T Cell Depletion. Biology of Blood and Marrow Transplantation, 2014, 20, 1322-1328.	2.0	13
115	Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group. Blood, 2014, 124, 424-424.	0.6	0
116	Value of EVI1 Gene Expression Level in Adult Acute Lymphoblastic Leukemia (ALL): A Study from the Group for Research on Adult ALL (GRAALL). Blood, 2014, 124, 1081-1081.	0.6	18
117	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i> –Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2013, 31, 4333-4342.	0.8	202
118	Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT. Bone Marrow Transplantation, 2013, 48, 408-413.	1.3	6
119	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of Clinical Oncology, 2013, 31, 3889-3897.	0.8	392
120	Reversible ventricular arrythmia induced by dasatinib. Clinical Case Reports (discontinued), 2013, 1, 20-25.	0.2	13
121	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	9
122	Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2012, 47, 236-242.	1.3	22
123	Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms. Biology of Blood and Marrow Transplantation, 2012, 18, 608-616.	2.0	43
124	High hyperdiploid acute lymphoblastic leukemia in adults shows clonal heterogeneity and chromosomal instability at diagnosis and during the course of the disease. Annals of Hematology, 2012, 91, 793-796.	0.8	3
125	Thirdâ€party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed postâ€hematopoietic stem cell transplantation. Pediatric Transplantation, 2012, 16, 131-136.	0.5	5
126	Towards a Purely Oncogenetic Risk Classification of Adult T-ALL: a GRAALL Study. Blood, 2012, 120, 881-881.	0.6	0

#	Article	IF	CITATIONS
127	Do NK Cells Contribute to the Pathophysiology of Transplant-Associated Thrombotic Microangiopathy?. American Journal of Transplantation, 2011, 11, 1748-1752.	2.6	7
128	Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2011, 87, 138-147.	1.1	17
129	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Severe Alpastic Anemia After Cyclophosphamide Plus Antithymocyte Globulin Conditioning Regimen,. Blood, 2011, 118, 4090-4090.	0.6	0
130	CD56 ^{bright} NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. European Journal of Immunology, 2010, 40, 3246-3254.	1.6	31
131	Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplantation, 2010, 45, 558-564.	1.3	56
132	5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07). Blood, 2010, 116, 2181-2181.	0.6	0
133	Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. Journal of Clinical Oncology, 2009, 27, 911-918.	0.8	506
134	Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and Tâ€cell depletion with Tâ€cell addâ€back. European Journal of Haematology, 2009, 83, 273-275.	1.1	4
135	Atypical presentation of acute myeloid leukemia: cardiac myeloid sarcoma. International Journal of Hematology, 2009, 89, 693-698.	0.7	16
136	PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia, 2009, 23, 1989-1998.	3.3	101
137	Cord blood banks collect units with different HLA alleles and haplotypes to volunteer donor banks: a comparative report from Swiss Blood stem cells. Bone Marrow Transplantation, 2009, 43, 771-778.	1.3	15
138	Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Blood, 2009, 114, 3080-3080.	0.6	7
139	Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Seminars in Immunopathology, 2008, 30, 425-437.	2.8	210
140	Quality of life and social integration after allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2008, 42, 819-827.	1.3	80
141	Steroid-responsive cauda equina syndrome associated with GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2008, 41, 315-316.	1.3	5
142	The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. Bone Marrow Transplantation, 2007, 40, 515-522.	1.3	59
143	Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-Leukemia Reaction? A Prospective Phase II Study. Biology of Blood and Marrow Transplantation, 2006, 12, 102-110.	2.0	47
144	Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. Bone Marrow Transplantation, 2006, 37, 909-916.	1.3	39

#	Article	IF	CITATIONS
145	Defibrotide Effectively Prevents Veno-Occlusive Disease of the Liver (VOD) after Allogeneic Stem Cell Transplantation. An Extended Study Blood, 2006, 108, 2962-2962.	0.6	0
146	Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients. Bone Marrow Transplantation, 2005, 35, 1171-1177.	1.3	75
147	Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 347-354.	2.0	123
148	Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD Blood, 2004, 104, 2239-2239.	0.6	0
149	Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Geneva experience. Leukemia, 2003, 17, 228-231.	3.3	48
150	Benefit of Prestorage Leukocyte Depletion of Single-Donor Platelet Concentrates. Vox Sanguinis, 1999, 76, 27-37.	0.7	18
151	Benefit of prestorage leukocyte depletion of single-donor platelet concentrates. Vox Sanguinis, 1999, 76, 27-37.	0.7	9
152	Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible	1.3	0

152hematopoietic stem cell transplantation. Bone Marrow Transplantation, 0, , .